Research results and mechanism of sodium glucose cotransporter 2 inhibitors in the treatment of heart failure / 中国医师杂志
Journal of Chinese Physician
;
(12): 637-640,F3, 2022.
Article
Dans Chinois
| WPRIM
| ID: wpr-932110
ABSTRACT
Sodium glucose cotransporter 2 inhibitor (SGLT2i) emerged as a new hypoglycemic agent, which can inhibit glucose reabsorption and thus play a hypoglycemic role. Recent studies have shown that SGLT2i not only lowers blood glucose, but also has a protective effect on the cardiovascular system, which may benefit patients with heart failure.The specific mechanism of action is still not fully elucidated. This paper aims to summarize the latest research results of SGLT2i in the treatment of heart failure, and analyze the possible mechanisms for clinical guidance.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Type d'étude:
Guide de pratique
langue:
Chinois
Texte intégral:
Journal of Chinese Physician
Année:
2022
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS